Innate Pursues Anti-Leukemic In EU

Lumoxiti Potentially Transformative For French Firm

02 Jan 2020

• By John Davis

Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.

Starting_Block — Innate Quickly Into Its Stride In 2020 • Source: Shutterstock

More from Anticancer

More from Therapy Areas